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ABSTRACT
The proposed antibody-dependent enhancement (ADE) mechanism for severe dengue virus (DENV) disease suggests that non-
neutralizing serotype cross-reactive antibodies generated during a primary infection facilitate entry into Fc receptor bearing
cells during secondary infection, resulting in enhanced viral replication and severe disease. One group of cross-reactive antibod-
ies that contributes considerably to this serum profile target the premembrane (prM) protein. We report here the isolation of a
large panel of naturally occurring humanmonoclonal antibodies (MAbs) obtained from subjects following primary DENV sero-
type 1, 2, or 3 or secondary natural DENV infections or following primary DENV serotype 1 live attenuated virus vaccination to
determine the antigenic landscape on the prM protein that is recognized by human antibodies. We isolated 25 prM-reactive hu-
manMAbs, encoded by diverse antibody-variable genes. Competition-binding studies revealed that all of the antibodies bound
to a single major antigenic site on prM. Alanine scanning-based shotgunmutagenesis epitope mapping studies revealed diverse
patterns of fine specificity of various clones, suggesting that different antibodies use varied binding poses to recognize several
overlapping epitopes within the immunodominant site. Several of the antibodies interacted with epitopes on both prM and E
protein residues. Despite the diverse genetic origins of the antibodies and differences in the fine specificity of their epitopes, each
of these prM-reactive antibodies was capable of enhancing the DENV infection of Fc receptor-bearing cells.
IMPORTANCE
Antibodies may play a critical role in the pathogenesis of enhanced DENV infection and disease during secondary infections. A
substantial proportion of enhancing antibodies generated in response to natural dengue infection are directed toward the prM
protein. The fine specificity of human prM antibodies is not understood. Here, we isolated a panel of dengue prM-specific human
monoclonal antibodies from individuals after infection in order to define the mode of molecular recognition by enhancing anti-
bodies. We found that only a single antibody molecule can be bound to each prM protein at any given time. Distinct overlapping
epitopes were mapped, but all of the epitopes lie within a single major antigenic site, suggesting that this antigenic domain forms
an immunodominant region of the protein. Neutralization and antibody-dependent enhanced replication experiments showed
that recognition of any of the epitopes within the major antigenic site on prMwas sufficient to cause enhanced infection of target
cells.
Infections due to the four dengue virus (DENV) serotypes(DENV1 to DENV4) continue to increase globally in both fre-
quency and severity (1, 2). There is currently no licensed vaccine
or approved drug treatment for dengue infection. Each of the
dengue virus serotypes is associated with disease, ranging in sever-
ity from a febrile flu-like illness to life threatening hemorrhagic
fever or shock. Gaining a better understanding of the pathogenesis
of severe dengue, especially in the setting of enhanced disease dur-
ing secondary infection, is of central importance for the develop-
ment of and testing of experimental DENV vaccines. The most
accepted model of how severe dengue disease develops pro-
poses that during secondary DENV infection preexisting cross-
reactive antibodies, induced following a previous primary
DENV infection, form infectious virus-antibody complexes
that efficiently enter and infect cells expressing Fc receptors,
resulting in increased viral replication and the release of cyto-
kines and vasoactive mediators that increase vascular permea-
bility, culminating in severe dengue disease (3). This process
has been termed antibody-dependent enhancement (ADE) of
infection and has been studied extensively using cell culture
and various animal models (4–7).
The Flaviviridae family comprises enveloped viruses possess-
ing a genome that is a single-stranded positive-sense RNA mole-
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cule, covered with capsid protein. The viral envelope has 180 cop-
ies each of the envelope (E) and membrane (M) glycoproteins. E
protein binds to receptors on target cells and mediates low-pH-
induced fusion between the viral and cellularmembranes required
for viral entry. Each of the two protomers in the E protein dimer
possesses three principal domains, designated domains I, II, and
III (DI, DII, andDIII) (8). DENVbinds to cellular receptors via an
N-linked glycan on DII, as well as other regions on E protein that
have not been well defined. The hydrophobic fusion loop is lo-
cated at the tip of DII. E protein forms homodimers that lie flat on
the surface of the mature virus. Units of three parallel E dimers
form 30 stable raft-like structures that cover the viral surface (9).
DENVs bud into the lumen of the endoplasmic reticulum (ER)
as immature virions, which subsequentlymature during secretion
out of cells. Immature virions have E and prM protein het-
erodimers that arrange into 60 trimeric spikes (10). During secre-
tion, immature virions enter an acidic trans-Golgi compartment
in which the cellular protease furin cleaves prM to generate E
protein dimers that lie flat on the viral surface. “The cleaved pr-
protein portion remains associated with the particle, overlying the
fusion loop of the E protein, which is likely to prevent formed
virus from fusing with intracellular membranes of the host pro-
ducer cell” (10). Upon release of the virus into the extracellular
environment, a neutral pH allows for the disassociation of the
pr-protein, and the mature virus then is able to bind to, and fuse
with, a new cell (10). The intracellular cleavage of prM by furin is
often inefficient, resulting in various degrees of immature virus
being present in cell culture-generated DENV preparations (11).
Fully immature particles, which continue to possess 180 copies of
prM protein, are considered noninfectious. However, when
bound by anti-prM antibodies, immature and partially mature
DENV can be taken up into and infect Fc receptor-bearing cells
such asmonocytes (12). The extent towhich immature or partially
immature DENVs are generated in vivo during a human infec-
tion remains unclear. The human antibody response to infec-
tion, however, contains antibodies directed toward the prM
protein (13, 14).
Studies of the human antibody response using monoclonal
antibodies (MAbs) developed following natural primary and sec-
ondary DENV infections show that the majority, 95%, target
cross-reactive epitopes (15–19). A substantial proportion of hu-
man antibodies that target surface-exposed proteins are directed
toward the prM protein (15, 16). These serotype cross-reacting
antibodies do not exhibit neutralizing properties in vitro, nor do
they demonstrate protection when studied in animal models of
DENV infection. In fact, several groups have shown that anti-prM
MAbs exhibit significant infection enhancing properties in cell
culture and in animal models of DENV infection (15, 16, 18, 20).
Moreover, immune sera from people exposed to primary DENV
infections contain prM antibodies that enhance heterologous se-
rotypes in cell culture and animalmodels of DENV infection (20).
Thus, anti-prM antibodies are likely to play an important role in
the pathogenesis of dengue disease in humans and may be a key
component of the proposedADEmechanismof infection hypoth-
esized to be at the center of the development of severe DENV
disease.
Mapping the epitopes targeted by the anti-prM protein anti-
body response is important for our basic understanding of the
pathogenesis of DENV infection and disease. Most studies of prM
human antibody reactivity to date have been conducted using
polyclonal sera. One murine anti-prMMAb designated 4D10 has
been reported, which wasmapped using phage display technology
to residues 14 to 18 of DENV1-4 prM protein (21). The clonal
basis for recognition of prM by human antibodies is not under-
stood.
We sought here to define the landscape of the human anti-prM
protein response at the clonal level in order to determine the num-
ber of antigenic sites on prM, identify the dominant epitope tar-
gets, and explore how the enhancing potencies exhibited by dif-
ferent MAbs relate to epitope specificity. We used B cells from
subjects with diverse serotypes of infection or vaccination to iso-
late 25 human MAbs to prM. The results show that all of the
antibodies recognize a single major antigenic site on the prM pro-
tein. Competition binding assays showed that only a single anti-
body molecule can engage a prM protein molecule at any given
time. Using alanine scanning-based shotgun mutagenesis map-
ping, it became clear that diverse antibodies exhibited minor dif-
ferences in fine specificity, since they target several different but
overlapping epitopes. Antibody-mediated virus neutralization
and infection enhancement experiments showed, however, that
recognition of any of the epitopes with the immunodominant site
could enhance replication.
MATERIALS AND METHODS
Human subjects and peripheral blood cell isolation.We identified sub-
jects in North Carolina and Tennessee who had acquired DENV infection
naturally by screening volunteers with suspected exposure during past
travel to regions where dengue is endemic. Subjects were confirmed to
have had DENV infection by testing their serum for the presence of anti-
bodies that neutralized each of the DENV serotypes. Peripheral blood
mononuclear cells (PBMCs) were isolated by density gradient separation
on Ficoll. The cells were cryopreserved immediately and stored in liquid
nitrogen until study. The protocol for recruiting and collecting blood
samples from subjects was approved by the Institutional Review Board of
the University of North Carolina at Chapel Hill and the Vanderbilt Uni-
versity Medical Center. Cryopreserved PBMCs from a repository of cells
from subjects previously infected in Nicaragua were kindly provided by
Eva Harris (University of California, Berkeley). Cryopreserved PBMCs
from a repository of cells from subjects vaccinated with two doses of a live
attenuated rDEN130 vaccine were kindly provided by Anna Durbin
(Johns Hopkins University) and Stephen Whitehead (National Institutes
of Health [NIH]). Informed consent was obtained from all subjects.
Generation of human hybridomas. Previously cryopreserved sam-
ples were thawed rapidly in a 37°C water bath and washed prior to trans-
formation with Epstein-Barr virus as described previously (15). Cultures
were incubated at 37°C with 5% CO2 for 10 days prior to screening for
antigen-specific cell lines with enzyme-linked immunosorbent assay
(ELISA). Cells from wells with supernatants reacting in DENV-specific
ELISA were then expanded prior to screening by flow cytometric neutral-
ization assay and cytofusion withHMMA2.5 nonsecretingmyeloma cells,
as previously described (15). After cytofusion, hybridomas were selected
by growth in hypoxanthine-aminopterin-thymidine (HAT) medium
containing ouabain and biologically cloned. Wells containing hybrid-
omas producing DENV-specific antibodies were cloned biologically by
three rounds of limiting dilution plating, by using a ClonePix device (Mo-
lecular Devices) according to the manufacturer’s recommendations or
using flow cytometric sorting with a single cell collection device. Once
clonality was achieved, each hybridoma was expanded until 50% conflu-
ent in 75-cm2 flasks. For antibody expression, the cells in the 75-cm2 flasks
were collected with a cell scraper; the hybridomas were washed in serum-
free medium (Gibco Hybridoma-SFM from Invitrogen, catalog no.
12045084) and split equally among four 225-cm2 flasks (Corning, catalog
no. 431082) containing 250 ml of serum-free medium. Flasks were incu-
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bated for 21 days before the medium was clarified by centrifugation and
0.2-m-pore-size sterile filtered. Antibodies were purified from clarified
medium by protein G chromatography (GE Life Sciences, protein G HP
columns).
Characterization of antibody isotype, subclass, and variable genes.
The isotype and subclass of secreted antibodies were determined by
ELISA. Nucleotide sequences of variable gene segments were determined
by Sanger sequencing from cloned cDNA generated by PCR with reverse
transcription amplification of cellularmRNA, using variable gene-specific
primers designed to amplify antibody genes from all gene families (22).
The identities of the gene segments and mutations from the germ line
sequences were determined by alignment using the ImMunoGeneTics
database (http://imgt.cines.fr) (23).
Viruses and recombinant proteins. DENV1 WestPac-74, DENV2
S-16803, DENV3 CH-53489, and DENV4 TVP-376 virus strains, pro-
vided by Robert Putnak (Walter Reed Army Institute of Research, Silver
Spring, MD), were used in the present study for both binding ELISA and
neutralization assays. Virus-containing supernatant used in virus capture
ELISAs was prepared in C6/36mosquito cells grown in completeminimal
essential medium (Gibco, catalog no. 51985-034).
Recombinant proteins representing fragments of E or prM-protein
were used to determine antigens and domains recognized by human
MAbs. Recombinant DENV proteins were constructed using the se-
quences of the above strains. Sequence optimization, gene synthesis, and
molecular cloning of all recombinant DENV protein constructs for ex-
pression in baculoviruswas performed byGenScriptUSA, Inc. The amino
acid residues for the E-protein constructs (rE) were as follows: DENV1 rE
(1 to 397), DENV2 rE (1 to 397), DENV3 rE (1 to 395), and DENV4 rE (1
to 397). The amino acid residues for the Pr-protein constructs (rPr) were
as follows: DENV1 rPr (1 to 86), DENV2 rPr (1 to 86), DENV3 rPr (1 to
86), and DENV4 rPr (1 to 86). Protein production and purification were
described previously (24).
ELISA using virus or recombinant protein antigens. For virus cap-
ture ELISA, purified mouse MAb 4G2, prepared in carbonate binding
buffer, was used to coat ELISA plates (Nunc, catalog no. 242757) and
incubated at 4°C overnight. After blocking for 1 h, plates were washed five
times with phosphate-buffered saline (PBS), and 50l of DENV-contain-
ing culture supernatant from infected C6/36 cell culture monolayers was
added. The plates then were washed ten times with PBS, and 5 l of
purified human MAb (1 g/l) was added to 25 l of blocking solution/
well. The plates were incubated at room temperature for 1 h prior to five
washes with PBS. Secondary antibody (goat anti-human Fc;Meridian Life
Science, catalog no. W99008A) was applied at a 1:5,000 dilution in block-
ing solution using 25l/well, and the plates again were incubated at room
temperature for 1 h. After repeat PBS washing (five times), phosphatase
substrate solution (1 mg/ml phosphatase substrate in 1 M Tris amino-
methane) (Sigma, catalog no. S0942) was added at 25 l/well, and the
plates were incubated at room temperature for 2 h before the optical
density was read at 405 nm on a BioTek plate reader.
For recombinant protein capture ELISA using E protein or prM con-
structs, purifiedmouse anti-Strep-tag II MAb (StrepMAB-Immo, catalog
no. IBA 2-1517-001) prepared in carbonate binding buffer was used to
coat ELISA plates (Nunc, catalog no. 242757), followed by incubation at
4°C overnight. After blocking for 1 h, the plates were washed five times
with PBS, and 50 l of recombinant protein construct containing culture
supernatant (cultured in insect cells) was added. The plates were then
washed ten times with PBS, and 5 l of purified human MAb (1 g/l)
was added to 25 l of blocking solution/well. All other steps were per-
formed as described above for the virus capture ELISA.
DENV Western blotting. The blots were performed using crude
whole DENV antigen or purified whole DENV antigen. The crude
DENV2 (strain S-16803) antigen was harvested from infected cell culture
medium, concentrated by centrifugation, and loaded onto a 4 to 12%
SDS-PAGE gel run under denaturing reducing conditions or nonreduc-
ing conditions. After transfer, the nitrocellulose membrane was probed
with the purified human MAb in question (diluted 1:1,000) for 1 h at
37°C. The membrane was washed three times with PBS-Tween and then
incubatedwith goat anti-human Fc-AP secondary (Meridian Life Science,
catalog no. W99008A) for 1 h at 37°C prior to washing and development
using BCIP/NBT chromogenic substrate (Invitrogen, catalog no.
WP20001). E-protein-specific MAbs were included as controls. Purified
whole DENV2 (strain NGC) antigenwas purchased from a vendor (Micro-
bix, Canada; catalog no. EL-22-02). A total of 1 g of the pure antigen was
loaded onto 12% SDS-PAGE gels under denaturing, nonreducing condi-
tions (without DTT).We blotted and tested the samples with three differ-
ent concentrations (0.5, 1, or 2.0 g/ml) of each of the prM antibodies.
We used goat anti-human horseradish peroxidase as the secondary anti-
body.
Neutralization assay. The neutralizing potency of MAbs was mea-
sured using a flow cytometry-based neutralization assay with the U937
human monocytic cell line stably transfected with DC-SIGN, as previ-
ously described (25, 26).
ADE assays. The ability of antibodies to enhance DENV infection was
measured using U937 cells that had not been engineered to express
DC-SIGN. In the absence of the virus attachment factor, these Fc recep-
tor-bearing cells are only susceptible to infection in the presence of
DENV-specific antibodies. The assay was performed as described in detail
previously (15). ADE activity was expressed as the percent increase of
infected cells in the DENV-specific antibody-treated sample compared to
the sample treated with a control antibody.
Epitope mapping using antibody competition. A biosensor instru-
ment using biolayer interferometry (Octet Red; ForteBio) was used for all
competition-binding studies. For competition assays, DENV2 virions
were produced in cell culture and immunoaffinity purified on the biosen-
sor tips. Briefly, purified biotinylated mouse anti-dengue virus prMMAb
2H2 was loaded onto streptavidin tips (ForteBio, catalog no. 18-5019).
Crude DENV2 S-16803 was prepared by centrifuging 250 ml of sterile-
filtered supernatant from infectedC6/36 cell culturemonolayers at 10,000
rpm for 12 h. The pellet containing crude virion particles was then sus-
pended in 5ml of PBS and captured on the biosensor tip usingMAb 2H2.
After a washing step, the first human anti-DENV MAb was added, fol-
lowed immediately by a second human MAb to assess binding interfer-
ence. The antibodies were judged to compete for the same site if maxi-
mum binding of the second antibody was reduced to25% of its binding
in the absence of the first antibody. No competition was achieved if max-
imum binding of the second antibody was 75% of its binding in the
absence of the first antibody.
Shotgun mutagenesis epitope mapping. DENV3 (strain CH53489)
and DENV4 (341750 strain) prM/E expression constructs were subjected
to high-throughput mutagenesis (“shotgun mutagenesis”) to generate
comprehensive mutation libraries. Random mutations were introduced
into the DENV3 prM/E polyprotein by PCR using a diversitymutagenesis
kit (Clontech Laboratories, Inc., Mountain View, CA), and for the
DENV4 construct primers were used to mutate each prM/E polyprotein
residue to alanine (and alanine codons to serine). In total, 1,400 DENV3
and 660 DENV4 mutants were generated (97% coverage of each sero-
type prM/E ectodomain), sequence confirmed, and arrayed into 384-well
plates (one mutation per well). Each anti-DENV antibody was screened
on the full DENV3 mutation library or a consolidated DENV3 library
containing a subset of the most relevant E protein mutations. Four MAbs
(1H7.2, 2H21, 2K2, and 5M22) were also screened on the DENV4 muta-
tion library. For screening, vectors for each DENV protein mutant were
transfected individually into human HEK-293T cells and allowed to ex-
press for 22 h before the cells were fixed in 4% paraformaldehyde (Elec-
tronMicroscopy Sciences) and permeabilizedwith 0.1% (wt/vol) saponin
(Sigma-Aldrich) in PBS plus calciumandmagnesium (PBS). The cells
were incubatedwith purifiedMAbs (0.1 to 2.0g/ml) diluted in 10%NGS
(Sigma)–0.1% saponin (pH9). The optimal primary antibody concentra-
tion was determined for each antibody using an independent immuno-
fluorescence titration curve against wild-type prM/E to ensure that signals
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were within the linear range of detection and that the signal exceeded the
background by at least 5-fold. Antibodies were detected using 3.75 g/ml
Alexa Fluor 488-conjugated secondary antibody (Jackson ImmunoRe-
search Laboratories) in 10% NGS–0.1% saponin. The cells were washed
three times with PBS/0.1% saponin, followed by two washes in PBS.
The mean cellular fluorescence was detected using a high-throughput
flow cytometer (Intellicyt). Antibody reactivity against each mutant pro-
tein clone was calculated relative to wild-type protein reactivity by sub-
tracting the signal from mock-transfected controls and normalizing that
value to the signal from wild-type protein-transfected controls for the
serotype tested. Mutations within clones were identified as critical to the
MAb epitope if they did not support reactivity of the test MAb but did
support reactivity of other antibodies. This counterscreen strategy facili-
tates the exclusion of DENV protein mutants that are misfolded or have
an expression defect. Critical amino acids required for antibody binding
were visualized on the DENV2 prM/E protein crystal structure PDB ID
3C6E (27).
RESULTS
HumanMAbs to the DENV prM protein.We isolated a panel of
human anti-prM protein MAbs from otherwise healthy human
subjects with diverse histories of DENV infection or vaccination.
A total of 25 humanMAbs were isolated; details about the donors
for the MAbs are shown in Table 1. MAbs were obtained from
individuals following DENV1, DENV2, or DENV3 primary natu-
ral infections or after vaccination with a monovalent DENV1 live
attenuated virus. We also obtained anti-prMMAbs from individ-
uals following secondary DENV infections, including one whose
secondary infection had been determined previously to be a result
of DENV1 and DENV3 exposures. The length of time from when
the subject experienced the infection until we obtained peripheral
blood samples for isolation of prM-specific B cells ranged from 1
to 24 years.
DENV antigen binding by ELISA orWestern blot.We tested
the ability of each member of this panel of MAbs to bind to anti-
gens from each of the four DENV serotypes in a virus capture
ELISA. As can be seen in Table 2, all 25 human anti-prM protein
MAbs isolated were serotype cross-reactive, binding to all four
dengue serotypes. We next tested binding against a recombinant
“pr” portion of the prM protein. All MAbs tested showed binding
to this recombinant protein, representing the cleaved portion of
the prM protein. We also tested binding of these prM-reactive
MAbs to recombinant DENV E protein in ELISA. Surprisingly,
twoMAbs, designated 2M2 and 5M22, bound to soluble E protein
in ELISA, in addition to binding to prM. We subjected MAbs to
Western blot analysis usingwhole virus preparationswith orwith-
out DTT reducing reagent. As expected, most of the MAbs tested
bound to a protein with the expected apparent molecular weight
of prM in theWestern blot, as can be seen in Fig. 1. FiveMAbs did
not show binding, or exhibited variable binding, in Western blot
analysis, likely due to SDS denaturation of the epitope structure
during the procedure. MAb 2M2 and to a lesser extent 5G22
bound to both prM protein and to a protein with the apparent
molecular weight of E protein (Fig. 1); MAb 5M22 also exhibited
this pattern (not shown). None of the MAbs bound when tested
under reducing conditions.
Functional properties of humananti-prMproteinMAbs.We
tested the functional properties of this panel ofMAbs by perform-
ing both neutralization and enhancement assays against proto-
typic viruses from each of the DENV serotypes. As can be seen in
TABLE 1 Subject demographics and serum serologiesa
Type of infection and
serotype(s) MAb Subject
Geographic location
of infection Date (yr)
Time (yr)
since
infection
Reciprocal serum antibody
50% neutralization titer to
various DENV serotypes
Study
referenceD1 D2 D3 D4
Primary
DENV1 2J9, 2H21,
2G3, 2B17,
1H7.2,
1E23
106 India 2007 2 90 15 13 11 24
DENV2 5M22 19 Thailand 1997 8 95  20 105 15
DENV3 1E16 118 Nicaragua 2009 1 60 32 980 76 19
1C6* 5110 Nicaragua 2010 1
2H12 3 Thailand 2001 4 30 87 338  15
5G22 and 4E9 105 Thailand 2002 7   210  15
Vaccine
rDENV130 1O6 39 NA 2009 0.6 189 ND ND ND 24
1L13 53 NA 2009 0.6 39 ND ND ND 24
Secondary
DENV1 and DENV3 1K20*, 1B22,
1H10, 1I12,
2K2, 4G21,
5E15
184 Mexico 2006 4 282 209 166 76 19
Multiple 1G10* 1089 Nicaragua 2009 1 107 220 200 70
4F8 15 West Indies 1972–1982 23 371 320 288  15
1G6 and 2M2 27 Thailand/Cambodia 1981 24    285 15
a, titer 1:1,280;, titer 1:20. *, Unpublished; NA, not applicable; ND, not determined.
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Table 2, with one exception, the members of this panel of human
anti-prM protein MAbs showed little or no neutralizing activity
against viruses from the four DENV serotypes. MAb 2M2, how-
ever, which bound to both E and prM protein in ELISA, did
weakly neutralize viruses of all four serotypes. MAb 5M22, which
also bound to both E and prMproteins, showedweak neutralizing
activity against DENV serotypes 1, 2, and 3.
We also evaluated the panel of MAbs for their ability to en-
hance the virus infection of FcR-bearing cells in culture. Each
MAbwas tested at a 1-g/ml concentration against viruses of each
of the four DENV serotypes. Each of the MAbs showed some
degree of infection-enhancing properties. A large proportion (15
of 25; 60%) of the MAbs exhibited very potent (25-fold) en-
hancement of replication forvirusof at leastone serotype.Fourof the
MAbs (designated 1G6, 4F8, 5E15, and 5G22) demonstrated 50-
fold enhancement of at least one DENV serotype at this concentra-
tion.MAb5G22showed thegreatestdegreeof enhancement, increas-
ing DENV3 infectivity by a remarkable 94-fold at the 1-g/ml
concentration tested.
Epitope mapping using antibody competition-binding ex-
periments. To better understand the antigenic landscape recog-
nized by the human prM antibody response, we performed MAb
competition-binding assays using DENV particles captured on a
biosensor tip and analyzed by biolayer interferometry. This exper-
imental strategy allowed real-time determination of antibody
binding to captured virus particles. Each of the human MAbs in
this panel fell into the same competition-binding group (see Fig.
S1 in the supplemental material), suggesting that all of them bind
to the same single major antigenic site on the prM protein. In
other words, the binding of any one antibody in the panel blocked
the binding of any other. As a control reagent we used the human
MAb 3D18 that recognizes the DENV E protein fusion loop (28)
when determining whether any of the MAbs in the panel could
bind exclusively to the portion of the E protein around the fusion
loop, which is in the area underlying prM in immature particles
(28). For several of the MAbs in the panel, we generated Fab frag-
ments to determine whether competition for binding could be
reduced or eliminated if the steric footprint was smaller. Again,
with an anti-prMprotein Fab bound to virus particles, none of the
full-length anti-prM pairs of MAbs that were tested could bind
simultaneously.
Epitopemapping using alanine scanning based shotgunmu-
tagenesis.We next set out to define the prM protein residues that
are critical for binding by theMAbs in the panel (see Fig. S2 in the
supplemental material). As seen in Fig. 2 and Table S1 in the
supplemental material, critical residues were determined for each
of the MAbs in the panel, with the exception of 2M2 and 4E9. In
several instances, critical residues were defined using mutant li-
braries based on both DENV3 and DENV4 prM/E proteins. De-
spite all MAbs falling into one competition-binding group, the
TABLE 2 Functional features of prM-reactive human MAbsa
MAb
Binding to whole virus in
ELISA, for the indicated
serotype, at 1 g/ml
Binding to protein
50% neutralization concn
(g/ml) against the
indicated serotype
Fold enhancement of
infection, for the indicated
serotype, at 1 g/mlELISA Western blotting
D1 D2 D3 D4
rE
protein
rPr
protein
E
protein
PrM
protein D1 D2 D3 D4 D1 D2 D3 D4
1B22     –  –  – – – – 2 1 1 3
1C6     –  –  – 9 4 – 18 22 35 32
1E16     –  – – – – – – 5 1 3 17
1E23     –  –  – – – – 4 1 5 4
1G6     –  –  – – 5 – 19 20 70 38
1G10     – ND – – – – – – 18 22 34 31
1H7.2     –  –  – – – – 5 2 3 5
1H10     –  –  – – – – 16 23 31 30
1I12     –  –  – – – – 3 2 2 6
1K20     – ND –  – – – – 16 23 27 36
1L13     –  –  – – – – 6 2 3 11
1O6     –  – – – – – – 17 23 32 29
2B17     –  –  – – – – 3 3 4 3
2G3     –  –  – – – – 3 1 3 9
2H12     –  –  – – 8 – 14 7 35 9
2H21     –  –  – – – – 3 1 1 4
2J9     –  –  – – – – 3 1 2 9
2K2     –  –  – – 2 – 17 26 25 30
2M2         1 0.5 2 1 17 8 8 48
4E9     –  –  – – 1 – 7 – 30 21
4F8     –  –  – – 2 5 13 15 57 24
4G21     –  –  – – – – 18 22 32 0.5
5E15     –  –  – – – – 20 20 61 24
5G22     –  /–  – – 6 – 40 12 94 46
5M22      ND  /– 7 9 5 – 11 11 42 11
a Binding to each DENV serotype and recombinant E and pr protein constructs are shown. The concentration (g/ml) at which 50% of virus was neutralized (neut50) is shown for
each DENV serotype: a dash indicates neut50 value 10 g/ml, neut50 values between 1.0 and 10.0 g/ml are shown, neut50 values 0.5 g/ml are indicated in boldface. ADE
assays were performed for each human antibody (at a concentration of 1 g/ml) against each DENV serotype and are shown as the fold enhancement:25-fold enhancement
values are indicated in boldface. –, Negative or none. ND, not done.
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results of this fine epitope mapping work demonstrated that re-
gions of the prM protein that are required for the binding of some
of the human MAbs differ. Seven commonly recognized residues
were identified (F1, L3, S5, E9, E18, L24, and K26), and there
were residues critical for the binding of over 50% of the MAbs in
the panel. Residue K26 was critical for the binding of 71% of the
MAbs. F1 or L3 residues also were found to be necessary for the
bindingof42or46%of theMAbs, respectively.We identified critical
residues within both prM and E protein for MAb 1G6. Figure 3
provides a prM protein map indicating the frequency of residues
participating in MAb epitopes; the reduction of binding for criti-
cal residues is shown in Table S2 in the supplementalmaterial.We
analyzed the distribution of residues recognized by MAbs from
donors with primary versus secondary infection and did not de-
tectmajor distinguishing patterns. Specifically, F1, L3, S5 E18, and
K26 contributed to the binding for MAbs derived from primary
and secondary cases; E9 contributed to the binding of 3 of 14
(21%) MAbs from primary and 0 of 11 (9%) MAbs from sec-
ondary cases.
Genetic features of the antibodies. Given that each of the
MAbs isolated recognized a single major antigenic site, it was pos-
sible that these diverse individuals were using a single dominant
antibody gene to encode a canonical antibody that is inherently fit
for binding to prM in the germ line configuration. To determine
whether such unique genetic features were characteristic of hu-
man anti-prM protein antibodies, we obtained heavy- and light-
chain-variable gene sequences for 23 clones and analyzed them for
variable gene usage and amino acid motifs (Table 3). We noted
that each of the antibodies was encoded by distinct variable gene
sequences using diverse VH, D, and JH gene segments. The VH1-69
segment was moderately over-represented, being found in 5 of 23
clones (22%). ThemeanHCDR3 length of 18.3was about 2 amino
acids longer than the typical mean of 16 in human B cells. Consis-
tent with this, many of the longer HCDR3 regions were encoded
by the longest D gene segments (D2 andD3 family members).We
also determined the light-chain usage and heavy-chain isotype/
subtype by ELISA to determine whether any of these features were
common in the prM panel.We found that all of the clones were of
the IgG1 isotype. Interesting, the lambda light chain was highly
over-represented, being found in 20 of 23 (87%) of clones. The
variable gene sequences did contain somatic mutations consistent
with a memory cell phenotype, but the number of mutations was
not unusual or excessive. Thus, there appears to be a lambda light-
chain bias in the response against prM; otherwise, there are no
distinguishing genetic features in the prM-specific repertoire.
DISCUSSION
We sought to improve our understanding of the molecular land-
scape of the human anti-prM protein antibody response by deter-
mining the number of antigenic sites, the dominant epitope tar-
gets, and how these epitopes relate to the enhancing potencies
exhibited by different MAbs. The results show that human MAbs
target several overlapping epitopes on the surface of prM protein,
but their footprints fall into a single major antigenic site. We did
not identify any particular relationship between the infection en-
hancing properties of the antibodies and the fine specificity of the
epitope. In fact, every prM antibody enhanced infection with vi-
ruses from each of the four serotypes, nomatterwhat the exposure
history of the donor or the fine epitope specificity. The findings
suggest that, as a class, prM antibodies mediate ADE using essen-
tially a single mode of action. All of the MAbs we isolated were
IgG1 subclass. It was also remarkable that this class of antibody
was common to every individual studied, nomatter what the type
of DENV exposure history. This panel of human MAbs was ob-
tained from human subjects following diverse types of DENV in-
fection, including DENV serotype 1, 2, or 3 primary or secondary
dengue virus infections, or followingDENV1 live attenuated virus
vaccination. We did not detect any major differences in the anti-
FIG1 Western blot of humanMAbs probed against DENV antigens. Centrifuge-concentrated crudeDENVwas loaded into a 4 to 12%SDS-PAGE gel run under
denaturing nonreducing conditions. After transfer, the nitrocellulosemembrane thenwas probedwith the indicated humanMAb. E-protein-specificMAbswere
included as controls. The “” or “–” symbols indicate samples tested with or without the addition of dithiothreitol reducing agent. MW, molecular weight in
thousands.
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bodies or the epitopes recognized by prM-specificMAbs based on
infecting serotype or primary versus secondary infection status.
Despite the common functional profile of these antibodies and
recognition of a single antigenic site, the members of the panel of
human MAbs exhibited a diversity of features that showed that
there are many antibodies and recognition features that target
humanMAbs to this site on both the antibody and the virus side of
the interface. We considered whether there was a canonical anti-
body in humans forming a public clonotype across individuals
that accounts for this common recognition pattern. Several anti-
body heavy-chain-variable (VH) genes have been associated spe-
cifically with recognition of structurally distinct viral epitopes, for
instance the association of VH1-46 gene use with rotavirus VP6-
specific antibodies (29–31), VH1-69 gene use in influenza hemag-
glutinin stem region antibodies (32, 33), or VH1-02 or VH1-46
gene use in human MAbs specific for the CD4 supersite on HIV
envelope protein (34). These gene associations generally derive
fromoptimal interacting amino acids encoded by antibody heavy-
chain complementarity region 2 (HCDR2). Other canonical
amino acid motifs have been identified in the antibody HCDR3,
encoded by the VH, diversity (D) and joining (J) genes, for in-
stance, the HIV neutralizing antibodies PG9 and PG16 (35). We
did not identify any such antibody gene associations in this panel
of antibodies to prM, even though they all recognize a singlemajor
antigenic site. These data suggest that it is likely that most if not all
individuals can make prM-specific ADE antibodies, and they can
do so using a diversity of antibody clones from a wide variety of
naive B cells.
FIG2 Epitopemapping of prM region antibodies by shotgunmutagenesis library screening.We performedfine epitopemapping by screening for loss of binding
to a DENV3 randommutagenesis library, and in some cases a DENV4 alanine scanning library. Critical residues are visualized as green spheres on the DENV2
prM/E protein crystal structure (PDB identifier 3C6E; 28). (A)Anti-prMMAbs that did not have residueK26 as critical for binding; (B) anti-prMMAbs that have
residue K26 as critical for binding; (C)MAbs that had critical residues in prM and in E.MAbsmarked by asterisks weremapped on both theDENV3 andDENV4
libraries (see Table S1 in the supplemental material).
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Diversity in mode of recognition by these antibodies also was
suggested by features of their binding characteristics. First,
epitopemapping studies identified seven different residues neces-
sary for binding of antibodies in the panel. There was a clear hier-
archical pattern, with certain prM residues most commonly in-
volved in the interaction. Residue K26was involved in the binding
of 17 human antibodies, while residues F1 and L3 were critical for
binding of nearly half of ourMAbs. These residues, along with E9,
E18, and L24, are highly conserved across the DENV complex.
This finding is the likely explanation for why this class of MAbs is
so universally serotype cross-reactive, since they target areas of the
prM protein that are highly conserved. Interestingly, critical resi-
dues were also identified in the E protein for MAb 1G6. These
residues were focused within the fusion loop and neighboring E
protein domain II. Interpreting the role of critical residues in E
protein for 1G6 antibody binding is complex. The point muta-
tion in the prM/E antigen on the surfaces of cells in the satura-
tion mutagenesis studies could destabilize or alter the fine
structure of prM and cause loss of binding or, alternatively, the
MAb may bind a quaternary epitope with contact residues in
both prM and E. In the ELISA, the prM and E components were
tested separately, and the MAb bound only to prM. Likely 1G6
binds a quaternary prM/E epitope in which most of the contact
residues are in prM, and this component of the epitope is suf-
ficient for binding in ELISA. Clearly, the mode of binding for
antibodies that bind to both prM and E is complex, with mo-
lecular recognition of quaternary epitopes that would be found
only on virus particles. This recognition pattern has been de-
scribed previously for a human anti-prM MAb that was iso-
lated by phage display (36). The significance of recognition of a
quaternary epitope involving both E and prM protein residues
for these human anti-prM protein antibodies is unclear, but
FIG 3 Percentage of MAbs containing specific prM region residues in the epitope. Colors show the percentage of MAbs for which the indicated residue
contributes to the epitope, as determined by the loss of binding in fine epitope mapping studies. Residues are visualized on the DENV2 prM/E protein crystal
structure (PDB identifier 3C6E).
TABLE 3 Genetic features of prM-reactive human MAbs
MAb
IgG
subclass
Light
chain
Heavy-chain-
variable genes
Junctional protein sequence
Heavy-chain CDR3
length (amino acids)
No. of somatic mutations in
heavy chains
VH D JH Nucleotides Amino acids
1B22 IgG1  1-69 2-2 6 CATLSLFCDSASCYHDPTSMDVW 21 34 18
1C6 IgG1  1-18 2-2 5 CAKMEDCNSTSCYGGTNWFDPW 20 23 10
1G6 IgG1  1-3 3-22 4 CARVNGDSAYYYGAPDYW 16 30 15
1G10 IgG1  3-15 2-2 6 CTTDLPLEYQLFYYDYMDVW 18 17 7
1H7.2 IgG1  3-23 2-15 4 CAKMGLCSGGSCYTGFIHFW 18 31 17
1H10 IgG1  4-4 3-3 3 CARVEFGFFGVVAKGIDLW 17 27 14
1I12 IgG1  3-74 3-3 5 CARGVNYDLWSAYSTDENWFDPW 21 12 9
1K20 IgG1  4-31 2-15 5 CARGRYCNDDSCYSEESAIWFDPW 22 25 17
1L13 IgG1  4-31 2-21 5 CATESYCRGNNCYPTPVIDPW 19 16 10
1O6 IgG1  1-69 2-2 5 CARATDCSTTSCYSSSWFDPW 19 21 14
2B17 IgG1  3-72 2-2 6 CAREGSCGSSTSCYADHYYGMDVW 22 13 9
2G3 IgG1  1-69 3-22 4 CATDTSGNLDFW 10 24 14
2H12 IgG1  3-49 3-3 4 CTQTPYCSGDKCYPVPFFDSW 19 17 11
2H21 IgG1  3-15 3-9 5 CATVEYCDATSCYNDDEAWFDPW 21 30 19
2J9 IgG1  3-49 2-15 5 CTRVVDCSGVNCYPMGWFDPW 19 15 7
2K2 IgG1  3-21 5-12 6 CARDRDTLPRDYYYHYGMDVW 19 20 9
2M2 IgG1  5-51 3-10 6 CGRHLYYFGSGKALLHGADVW 19 24 15
4E9 IgG1  3-11 2-15 1 CARGPEGYCSGNNCYPAEYFQHW 21 17 9
4F8 IgG1  4-59 2-8 3 CAISLGYCTGGKCHSGLGTFDIW 21 18 14
4G21 IgG1  1-69 5-12 4 CATDSGYVFYFGYW 12 7 4
5E15 IgG1  3-30 2-2 3 CTGGLGYCSSSSCYLGAFDVW 19 28 18
5G22 IgG1  3-53 1-26 4 CARGGSFYDPFDYW 12 8 4
5M22 IgG1  1-69 2-2 5 CARETSCSSSSCYGTNWFDPW 19 19 10
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both 2M2 and 5M22 are some of the few neutralizing MAbs
that recognize prM.
Our shotgun mutagenesis approach identifies epitopes irre-
spective of MAb neutralization status or viral fitness and so is not
limited to inhibitory MAbs or to mutations that are compatible
with virus replication. Nonetheless, this strategy cannot detect the
contribution of alpha carbons to an interaction, mutations to
other substitutions could result in different results, and the ability
to differentiate direct from indirect or allosteric effects on MAb
interactions depends on the number and diversity of other avail-
able control MAbs. However, the concordance of mutagenesis,
competition binding, ELISA, andWestern blot data provides con-
fidence that the epitope residues identified here are accurate.
Other residues may also be involved in each epitope, but their
mutation may have resulted in misfolding of the protein, or they
did not disrupt the energetics of binding significantly enough to be
identified as critical.
The number of antibodies that can bind one prM proteinmol-
ecule is one factor that may contribute to the complexity of anti-
body-dependent enhancement. Only one antibody binding group
was identified by MAb competition-binding assays using whole
virus particles. These data suggest that, despite the overall com-
plexity of the human anti-prM protein antibody response, only a
single antibody molecule is bound to one molecule of the prM
protein in immature particles at a given moment in time. There-
fore, anti-prM antibodies must be in a state of competition with
one another for binding to the single accessible site. This dynamic
is also complicated by the fact that the occupancy of antibodies on
the population of prM molecules on a single particle may not be
complete, andmost particles likely contain amixture of cleaved or
uncleaved prM/E protein. In the case of the polyclonal antibody
response in serum, the antibody concentration, affinity, and
epitope availability are likely to play a critical role in determining
which anti-prM antibodies are most successful in engaging the
virus.
In summary, the human antibody response encoding DENV
prM protein-specific antibodies is complex in terms of their ge-
netic origins and fine specificity, but these antibodies exhibit con-
sistent functional properties. These antibodies are cross-reactive,
possess very limited neutralizing properties, and are potent at in-
fection enhancement in vitro. The human prM protein-specific
antibody response targets diverse epitopes while competing for
binding to a single antigenic site. Continued discovery of the
structure and nature of the epitopes for this unique group of
MAbs in the future could point the way toward rational design of
DENV vaccine antigens to minimize the cross-reactive disease-
enhancing antibody profiles of those receiving the vaccine. Devel-
opment of vaccine preparations that have reduced tendencies to
induce prM-specific antibodies, such as viruses or particles lack-
ing the immunodominant K26 residue, could be considered.
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